- NEWS
Common antidepressant slashes risk of COVID death, study says
A cheap, widely available drug used to treat mental illness cuts both the risk of death from COVID-19 and the need for people with the disease to receive intensive medical care, according to clinical-trial results1.
The drug, called fluvoxamine, is taken for conditions including depression and obsessive–compulsive disorder. But it is also known to dampen immune responses and temper tissue damage, and researchers credit these properties with its success in the recent trial. Among study participants who took the drug as directed and did so in the early stages of the disease, COVID-19-related deaths fell by roughly 90% and the need for intensive COVID-19-related medical care fell by roughly 65%.
“A major victory for drug repurposing!” Vikas Sukhatme at Emory University School of Medicine in Atlanta, Georgia, who studies drug repurposing, wrote in an e-mail to Nature. “Fluvoxamine treatment should be adopted for those at high risk for deterioration who are not vaccinated or cannot receive monoclonal antibodies.”
COVID antibody treatments show promise for preventing severe disease
Study co-author Angela Reiersen, a psychiatrist at Washington University School of Medicine in St Louis, Missouri, has long been interested in using fluvoxamine to treat a rare genetic condition. While monitoring the fluvoxamine literature before the pandemic, she came across a 2019 study showing that fluvoxamine reduced inflammation in mice with sepsis2. When COVID-19 hit, “I immediately thought back to that paper with the mice,” she says.
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
24,99 € / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
204,58 € per year
only 4,01 € per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
doi: https://doi.org/10.1038/d41586-021-02988-4
References
Reis, G. et al. Lancet Glob. Health https://doi.org/10.1016/S2214-109X(21)00448-4 (2021).
Rosen, D. A. et al. Sci. Transl. Med. https://doi.org/10.1126/scitranslmed.aau5266 (2019).

COVID vaccines to reach poorest countries in 2023 — despite recent pledges
How antiviral pill molnupiravir shot ahead in the COVID drug hunt
Coronavirus breakthrough: dexamethasone is first drug shown to save lives
The race for antiviral drugs to beat COVID — and the next pandemic
Hopes rise for coronavirus drug remdesivir